相关实验视频
Updated: Jun 18, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
人环素诱导的心脏功能障碍:每个临床医生应该知道的内容
Armando Ferrera1, Vincenzo Fiorentini1, Simone Reale1
1Clinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
人环素可以改善癌症的存活率,但可以导致心力衰竭. 本综述详细介绍了环素心脏毒性,涵盖了其机制,诊断和预防策略,以管理患者的护理.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗在过去二十年里显著改善了癌症患者的生存率.
- 然而,化疗剂,特别是人环素,可以引起严重的副作用,包括心脏毒性.
- 人环素诱导的心脏毒性可能导致心力衰竭,限制治疗疗效和患者的结果.
研究的目的:
- 审查当前关于 antracycline 心脏毒性的证据.
- 为了探索类别和分子机制的环素诱导的心脏损伤.
- 为管理心脏毒性提供诊断,治疗和预防策略的概述.
主要方法:
- 对有关 antracyclines 和心脏毒性的现有研究的文献综述.
- 对有关分子机制,诊断和管理的数据进行分析.
- 综合目前关于预防和治疗方法的证据.
主要成果:
- 人环素与显著的心脏风险有关,包括心力衰竭.
- 了解分子通路对于识别风险患者至关重要.
- 早期诊断和主动管理是缓解心血管损伤的关键.
结论:
- 及时识别和管理 antracycline 心脏毒性是必不可少的.
- 有效的策略可以防止治疗中止,并改善患者的生存率.
- 管理心脏毒性可以改善癌症患者的短期和长期心血管健康.
相关概念视频
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Mechanism of Cardiac Arrhythmias
909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413

